Pfizer Inc. (PFE)
| Market Cap | 137.93B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.38 |
| PE Ratio | 17.54 |
| Forward PE | 8.61 |
| Dividend | $1.72 (7.09%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 25,602,642 |
| Open | 24.21 |
| Previous Close | 24.31 |
| Day's Range | 24.07 - 24.37 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 29.92 (+23.33%) |
| Earnings Date | Jul 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $29.92, which is an increase of 23.33% from the latest price.
News
Pfizer Declares Third-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to...
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding...
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced D...
Top stock price forecast: Plug Power, Uber, and Pfizer
The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures...
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
The Dark Side Of Dividend Growth Investing
Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend ...
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...
Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out
Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare po...
Pfizer: An Offensive Play For A Bear Market
The market has become overly pessimistic on Pfizer, focusing on the patent cliff while ignoring the defensive cash flows and offensive catalysts. This has created a classic value opportunity. A fortre...
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, c...
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
50% Off - 2 Dividend Gems With Huge Income And Growth Potential
Investing capital means balancing risk, goals, and timing, especially when markets face uncertainty and shifting global dynamics. I focus on long-term value and income. I highlight two undervalued opp...
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...
Two Alternatives For A Potential $5000 Monthly Income
Traditionally, a large portion of equity returns has come from two factors - reinvested dividends and compounding. We present two income-focused approaches: a fund-based portfolio for hands-off invest...
Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland
U.S. firms remain attracted to Ireland's strong business environment built on favorable tax treatment of intellectual property.
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YC...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare
Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples, making it attractive for income-focused investors despite recent underperformance. The company faces significant patent ...
Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Pfizer Inc. (NYSE:PFE) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asa...